Serolisa™ Human nFGF-21 ELISA Kit
This “sandwich” ELISA (enzyme-linked immunosorbent assay) kit is intended for the quantitative determination of human N-terminal FGF-21 level in EDTA-plasma or serum. It measures both the intact FGF-21 and the N-terminal FGF-21 fragments that are not N-terminally truncated, while the C-terminal end of the FGF-21 may be truncated. The test may be useful in clinical study related to diabetes and obesity, and is for research use only.
This ELISA kit is for research use only. Not for use in diagnostic procedures.
Fibroblast growth factor 21 (FGF-21) belongs to the FGF-19 subfamily, which includes FGF-19, FGF-21, and FGF-23. The FGF-19 family members are potent endocrine hormones in the regulation of a diverse physiological homeostasis.
The intact FGF-21 is a small protein comprising of 181 amino acids. Administration of recombinant FGF-21 lowered plasma glucose and insulin levels, reduced hepatic and circulating triglyceride and cholesterol levels, and improved insulin sensitivity, energy expenditure, hepatic steatosis, and obesity in a range of insulin-resistant animal models.
The physiological functions of FGF-21 rely on the intact molecular structure and animno acid sequence in its N-terminal and C-terminal region. The N-terminal non-truncated FGF-21 is a potent cell membrane FGF receptor binder. The N-terminal-truncated FGF-21 (7-181) is a potent inhibitor that competitively inhibits the biological activity of intact FGF-21 (1-181). Therefore, it is important to measure the amount of circulating, intact FGF-21 levels in the assessment of physiological and pathophysiological condition. An assay that determines FGF-21 fragments may overestimate the biological activity of the protein in test samples.
Circulating FGF-21 is a biomarker and its levels are increased in patients with nonalcoholic fatty liver disease (NAFLD), type 2 diabetes, gestational diabetes, and obesity. An increase of circulating FGF-21 is also found in patients with Cushing's syndrome and patients with lipodystrophy induced by HIV-1, as well as those with chronic renal disease or end-stage renal disease (ESRD).
Tests Per Kit
Sensitivity / LLOD
Total Incubation Time
4.7 pg /mL
0 - 2100 pg/mL
2 hour, 20 minutes
For research use only. Not for use in diagnostic procedures.